CD44 and pulmonary fibrosis: Administration of monoclonal antibodies directed against CD44 (e.g., clone IM7) to mice resulted in a significant attenuation of the progression of liver and lung fibrosis, which was accompanied by a reduction in the expression of activated myofibroblast markers (e.g., α-SMA) and a decrease in the collagen content in the ECM [201].